109 related articles for article (PubMed ID: 12025960)
1. A bradykinin antagonist and a caspase inhibitor prevent severe pulmonary hypertension in a rat model.
Taraseviciene-Stewart L; Gera L; Hirth P; Voelkel NF; Tuder RM; Stewart JM
Can J Physiol Pharmacol; 2002 Apr; 80(4):269-74. PubMed ID: 12025960
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of the VEGF receptor 2 combined with chronic hypoxia causes cell death-dependent pulmonary endothelial cell proliferation and severe pulmonary hypertension.
Taraseviciene-Stewart L; Kasahara Y; Alger L; Hirth P; Mc Mahon G; Waltenberger J; Voelkel NF; Tuder RM
FASEB J; 2001 Feb; 15(2):427-38. PubMed ID: 11156958
[TBL] [Abstract][Full Text] [Related]
3. Severe pulmonary arterial hypertension induced by SU5416 and ovalbumin immunization.
Mizuno S; Farkas L; Al Husseini A; Farkas D; Gomez-Arroyo J; Kraskauskas D; Nicolls MR; Cool CD; Bogaard HJ; Voelkel NF
Am J Respir Cell Mol Biol; 2012 Nov; 47(5):679-87. PubMed ID: 22842496
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of VEGF receptors causes lung cell apoptosis and emphysema.
Kasahara Y; Tuder RM; Taraseviciene-Stewart L; Le Cras TD; Abman S; Hirth PK; Waltenberger J; Voelkel NF
J Clin Invest; 2000 Dec; 106(11):1311-9. PubMed ID: 11104784
[TBL] [Abstract][Full Text] [Related]
5. A novel rat model of pulmonary hypertension induced by mono treatment with SU5416.
Chen Y; Kuang M; Liu S; Hou C; Duan X; Yang K; He W; Liao J; Zheng Q; Zou G; Chen H; Yan H; Chen J; Li Y; Zhou Y; Luo X; Jiang Q; Tang H; Lu W; Wang J
Hypertens Res; 2020 Aug; 43(8):754-764. PubMed ID: 32472112
[TBL] [Abstract][Full Text] [Related]
6. C-type natriuretic peptide does not attenuate the development of pulmonary hypertension caused by hypoxia and VEGF receptor blockade.
Casserly B; Mazer JM; Vang A; Harrington EO; Klinger JR; Rounds S; Choudhary G
Life Sci; 2011 Sep; 89(13-14):460-6. PubMed ID: 21820448
[TBL] [Abstract][Full Text] [Related]
7. Contribution of reactive oxygen species to the pathogenesis of pulmonary arterial hypertension.
Jernigan NL; Naik JS; Weise-Cross L; Detweiler ND; Herbert LM; Yellowhair TR; Resta TC
PLoS One; 2017; 12(6):e0180455. PubMed ID: 28666030
[TBL] [Abstract][Full Text] [Related]
8. The effects of antiangiogenic compound SU5416 in a rat model of pulmonary arterial hypertension.
Sakao S; Tatsumi K
Respiration; 2011; 81(3):253-61. PubMed ID: 21116108
[TBL] [Abstract][Full Text] [Related]
9. SU5416 plus hypoxia but not selective VEGFR2 inhibition with cabozantinib plus hypoxia induces pulmonary hypertension in rats: potential role of BMPR2 signaling.
Sitapara R; Sugarragchaa C; Zisman LS
Pulm Circ; 2021; 11(3):20458940211021528. PubMed ID: 34178306
[TBL] [Abstract][Full Text] [Related]
10. Detrimental Impact of Vasopressin V2 Receptor Antagonism in a SU5416/Hypoxia/Normoxia-Exposed Rat Model of Pulmonary Arterial Hypertension.
Goto I; Dohi K; Ogihara Y; Okamoto R; Yamada N; Mitani Y; Ito M
Circ J; 2016; 80(4):989-97. PubMed ID: 26924211
[TBL] [Abstract][Full Text] [Related]
11. The effects of the 5-HT2A receptor antagonist sarpogrelate hydrochloride on chronic hypoxic pulmonary hypertension in rats.
Geng J; Fan FL; He S; Liu Y; Meng Y; Tian H; Zhang D; Ma Q; Zhang JB; Tian HY
Exp Lung Res; 2016 May; 42(4):190-8. PubMed ID: 27191897
[TBL] [Abstract][Full Text] [Related]
12. VEGF-R blockade causes endothelial cell apoptosis, expansion of surviving CD34+ precursor cells and transdifferentiation to smooth muscle-like and neuronal-like cells.
Sakao S; Taraseviciene-Stewart L; Cool CD; Tada Y; Kasahara Y; Kurosu K; Tanabe N; Takiguchi Y; Tatsumi K; Kuriyama T; Voelkel NF
FASEB J; 2007 Nov; 21(13):3640-52. PubMed ID: 17567571
[TBL] [Abstract][Full Text] [Related]
13. Sarpogrelate hydrochloride, a serotonin 5HT2A receptor antagonist, ameliorates the development of chronic hypoxic pulmonary hypertension in rats.
Zhang E; Maruyama J; Yokochi A; Mitani Y; Sawada H; Nishikawa M; Ma N; Maruyama K
J Anesth; 2015 Oct; 29(5):715-23. PubMed ID: 25931318
[TBL] [Abstract][Full Text] [Related]
14. Cyclooxygenase inhibitors attenuate bradykinin-induced vasoconstriction in septic isolated rat lungs.
Fischer LG; Hollmann MW; Horstman DJ; Rich GF
Anesth Analg; 2000 Mar; 90(3):625-31. PubMed ID: 10702448
[TBL] [Abstract][Full Text] [Related]
15. Attenuation of pulmonary vascular hypertension and cardiac hypertrophy with sitaxsentan sodium, an orally active ET(A) receptor antagonist.
Tilton RG; Munsch CL; Sherwood SJ; Chen SJ; Chen YF; Wu C; Block N; Dixon RA; Brock TA
Pulm Pharmacol Ther; 2000; 13(2):87-97. PubMed ID: 10799286
[TBL] [Abstract][Full Text] [Related]
16. A Selective Transforming Growth Factor-β Ligand Trap Attenuates Pulmonary Hypertension.
Yung LM; Nikolic I; Paskin-Flerlage SD; Pearsall RS; Kumar R; Yu PB
Am J Respir Crit Care Med; 2016 Nov; 194(9):1140-1151. PubMed ID: 27115515
[TBL] [Abstract][Full Text] [Related]
17. Treatment of severe pulmonary hypertension: a bradykinin receptor 2 agonist B9972 causes reduction of pulmonary artery pressure and right ventricular hypertrophy.
Taraseviciene-Stewart L; Scerbavicius R; Stewart JM; Gera L; Demura Y; Cool C; Kasper M; Voelkel NF
Peptides; 2005 Aug; 26(8):1292-300. PubMed ID: 15878794
[TBL] [Abstract][Full Text] [Related]
18. Role of angiotensin-converting enzyme and angiotensin II in development of hypoxic pulmonary hypertension.
Morrell NW; Morris KG; Stenmark KR
Am J Physiol; 1995 Oct; 269(4 Pt 2):H1186-94. PubMed ID: 7485548
[TBL] [Abstract][Full Text] [Related]
19. Sulfated dehydropolymer of caffeic acid: In vitro anti-lung cell death activity and in vivo intervention in emphysema induced by VEGF receptor blockade.
Truong TM; Li H; Dhapare S; Desai UR; Voelkel NF; Sakagami M
Pulm Pharmacol Ther; 2017 Aug; 45():181-190. PubMed ID: 28648907
[TBL] [Abstract][Full Text] [Related]
20. SU5416 does not attenuate early RV angiogenesis in the murine chronic hypoxia PH model.
Peloquin GL; Johnston L; Damarla M; Damico RL; Hassoun PM; Kolb TM
Respir Res; 2019 Jun; 20(1):123. PubMed ID: 31208454
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
